Bupropion as a modulator of drug activity
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of treating major depressive disorder, comprising administering a dosage form by mouth once daily or twice daily to a human patient in need thereof, wherein the dosage form comprises about 105 mg of bupropion hydrochloride and about 45 mg of a dextromethorphan salt as the only therapeutically active compounds in the dosage form, wherein bupropion hydrochloride is in a sustained release formulation and the dextromethorphan salt is in an immediate release formulation, wherein the human patient does not experience an adverse event as a result of receiving the dosage form, and wherein the adverse event is seizure.
2. The method of claim 1 , wherein the dosage form is a tablet.
3. The method of claim 1 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max of bupropion in the human patient is about 9×10 1 ng/mL.
4. The method of claim 1 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12 of bupropion in the human patient is about 7×10 2 ng·hr/mL.
5. The method of claim 1 , wherein the dextromethorphan salt is dextromethorphan hydrobromide.
6. The method of claim 5 , wherein the dosage form is a tablet.
7. The method of claim 5 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max of bupropion in the human patient is about 9×10 1 ng/mL.
8. The method of claim 5 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12 of bupropion in the human patient is about 7×10 2 ng·hr/mL.
9. The method of claim 5 , wherein the human patient is an extensive CYP2D6 metabolizer.
10. The method of claim 9 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter.
11. The method of claim 1 , wherein the human patient is an extensive CYP2D6 metabolizer.
12. The method of claim 11 , wherein the dosage form is a tablet.
13. The method of claim 11 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max of bupropion in the human patient is about 9×10 1 ng/mL.
14. The method of claim 11 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12 of bupropion in the human patient is about 7×10 2 ng·hr/mL.
15. The method of claim 1 , wherein the dosage form is administered once daily by mouth for three days followed by twice daily by mouth thereafter.
16. The method of claim 15 , wherein the human patient is an extensive CYP2D6 metabolizer.
17. The method of claim 15 , wherein the dosage form is a tablet.
18. The method of claim 16 , wherein the dosage form is administered for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the C max of bupropion in the human patient is about 9×10 1 ng/mL.
19. The method of claim 16 , wherein the dosage form is administered for a total of at least 8 days, and wherein on the eighth day that the dosage form is administered, the AUC 0-12 of bupropion in the human patient is about 7×10 2 ng·hr/mL.